142 related articles for article (PubMed ID: 4279185)
1. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
Sommer H; Fischer GJ; Quandt J
Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
[No Abstract] [Full Text] [Related]
2. [Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
Piccirilli M; Quartesan R
Clin Ter; 1976 Mar; 76(5):467-77. PubMed ID: 991553
[No Abstract] [Full Text] [Related]
3. [Problems in the administration of L-DOPA (author's transl)].
Ferrari E
Riv Patol Nerv Ment; 1974 Aug; 95(4):239-50. PubMed ID: 4283417
[No Abstract] [Full Text] [Related]
4. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
[No Abstract] [Full Text] [Related]
5. [Side-effects of L-dopa therapy].
Girke W; Xenakis Ch
Dtsch Med Wochenschr; 1975 Oct; 100(42):2165-9. PubMed ID: 1100342
[No Abstract] [Full Text] [Related]
6. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
Cinca I; Serbănescu A; Tudorache B
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
[No Abstract] [Full Text] [Related]
7. [Treatment of Parkinson's disease with L-dopa. 77 cases].
Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
[No Abstract] [Full Text] [Related]
8. [Long-term levodopa syndrome. Report of a clinical case].
Bossi L; Nobili M
Arch Sci Med (Torino); 1978; 135(4):637-9. PubMed ID: 756726
[TBL] [Abstract][Full Text] [Related]
9. [Biochemical-pharmacological basis for the clinical use of L-dioxypheny alanine in Parkinson's syndrome].
Hornykiewicz VO
Wien Med Wochenschr; 1975 May; 125(21):325-7. PubMed ID: 1216856
[No Abstract] [Full Text] [Related]
10. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
11. [Parosmia and anosmia under L-dopa therapy (author's transl)].
Neundörfer B; Valdivieso T
Nervenarzt; 1977 May; 48(5):283-4. PubMed ID: 895952
[No Abstract] [Full Text] [Related]
12. Parkinson's disease in 1984: an update.
Lang AE; Blair RD
Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
[TBL] [Abstract][Full Text] [Related]
13. The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
Foster HD; Hoffer A
Med Hypotheses; 2004; 62(2):177-81. PubMed ID: 14962622
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
Merello M; Nouzeilles MI; Arce GP; Leiguarda R
Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
[No Abstract] [Full Text] [Related]
16. [Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
Fischer PA
Nervenarzt; 1974 Dec; 45(12):617-27. PubMed ID: 4614096
[No Abstract] [Full Text] [Related]
17. Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Lindner MD; Plone MA; Mullins TD; Winn SR; Chandonait SE; Stott JA; Blaney TJ; Sherman SS; Emerich DF
Exp Neurol; 1997 May; 145(1):130-40. PubMed ID: 9184116
[TBL] [Abstract][Full Text] [Related]
18. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
Yokochi M
Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189
[No Abstract] [Full Text] [Related]
19. [Risks of modern therapy for parkinsonism, and their consequences (author's transl)].
Jörg J; Kleine D
Nervenarzt; 1979 Jan; 50(1):33-42. PubMed ID: 424033
[No Abstract] [Full Text] [Related]
20. [Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Dolezalová B; Vacek J
Cesk Psychiatr; 1976 Dec; 72(6):403-7. PubMed ID: 1000706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
